In the Claims:

1. (currently amended) Use of deoxypeganine, in the form of a free base or in the form of an acid addition salt, or of a derivative of deoxypeganine as long as said derivative is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase, for producing a medicament for treating a schizophrenic psychosis which is connected with at least one of increased monoamine oxidase activity ~~and/or~~ and decreased functionality ~~(decreased activity or decreased expression)~~ of nicotinic acetylcholine receptors.
2. (currently amended) [[Use]] The use according to claim 1, wherein ~~characterized in that~~ the medicament contains the active substance deoxypeganine in proportions of 0.1 to 90%-wt~~, preferably 2 to 20% wt,~~ calculated as free deoxypeganine.
3. (currently amended) [[Use]] The use according to claim 1, wherein ~~or 2, characterized in that~~ said medicament has a depot effect.
4. (currently amended) [[Use]] The use according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ said medicament ~~is a medicament that~~ can be administered orally.
5. (currently amended) [[Use]] The use according to claim 1, wherein ~~any one of claims 1 to 3, characterized in that~~ said medicament ~~is a medicament that~~ can be administered parenterally.
6. (currently amended) [[Use]] The use according to claim 5, wherein ~~characterized in that~~ said medicament ~~is a medicament that~~ can be administered transdermally.
7. (currently amended) Use of deoxypeganine, in the form of a free base or in the form of an acid addition salt, or of a derivative of deoxypeganine as long as said derivative is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase, for treating a schizophrenic psychosis which is connected with at least one of increased monoamine oxidase activity ~~and/or~~ and decreased functionality ~~(decreased activity or decreased expression)~~ of nicotinic acetylcholine receptors.
8. (currently amended) [[Use]] The use according to claim 7, wherein ~~characterized in that~~ the administered daily dose is in the range 0.1 to 100 mg~~, preferably 10 to 50 mg~~.
9. (currently amended) [[Use]] The use according to claim 7, wherein ~~or 8, characterized in that~~ deoxypeganine is administered in a pharmaceutical

preparation containing the active substance in proportions of 0.1 to 90%-wt~~, preferably 2 to 20% wt~~, calculated as free deoxypeganine.

10. (currently amended) [[Use]] The use according to claim 9, wherein ~~characterized in that~~ deoxypeganine is administered in a pharmaceutical preparation having a depot effect.

11. (currently amended) [[Use]] The use according to claim 9, wherein ~~or 10, characterized in that~~ deoxypeganine is administered orally.

12. (currently amended) [[Use]] The use according to claim 9, wherein ~~or 10, characterized in that~~ deoxypeganine is administered parenterally.

13. (currently amended) [[Use]] The use according to claim 12, wherein ~~characterized in that~~ deoxypeganine is administered transdermally.

14. (currently amended) [[Use]] The use according to claim 7, wherein ~~any one of the preceding claims, characterized in that the~~ said nicotinic acetylcholine receptors are nicotinic acetylcholine receptors of the alpha 7 subtype.

15. (currently amended) [[Use]] The use according to claim 7, wherein ~~any one of the preceding claims, characterized in that the~~ said derivative of deoxypeganine, as long as it is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase, is selected from the group consisting of 7-bromodeoxypeganine, 7-bromo-6-hydroxy-5-methoxydeoxypeganine, 7-chloro-6-hydroxy-5-methoxydeoxypeganine, 7-fluoro-6-hydroxy-5-methoxydeoxypeganine, 7-iodo-6-hydroxy-5-methoxydeoxypeganine, 1,2,3,9-tetrahydro-6,7-methylenedioxypyrrolo[2,1-b]chinazoline and 2,3-dihydro-6,7-dimethoxypyrrolo[2,1-b]quinazoline-9(1H)-on.

16. (new) The use according to claim 1, wherein the decreased functionality of nicotinic acetylcholine receptors is decreased activity or decreased expression.

17. (new) The use according to claim 2, wherein the medicament contains the active substance deoxypeganine in proportions of 2 to 20%-wt, calculated as free deoxypeganine

18. (new) The use according to claim 7, wherein the decreased functionality of nicotinic acetylcholine receptors is decreased activity or decreased expression.

19. (new) The use according to claim 8, wherein the administered daily dose is in the range 10 to 50 mg.

20. (new) The use according to claim 9, wherein deoxypeganine is administered in a pharmaceutical preparation containing the active substance in proportions of 2

to 20%-wt, calculated as free deoxypeganine.

21. (new) The use according to claim 1, wherein said nicotinic acetylcholine receptors are nicotinic acetylcholine receptors of the alpha 7 subtype.

22. (new) The use according to claim 1, wherein said derivative of deoxypeganine, as long as it is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase, is selected from the group consisting of 7-bromodeoxypeganine, 7-bromo-6-hydroxy-5-methoxydeoxypeganine, 7-chloro-6-hydroxy-5-methoxydeoxypeganine, 7-fluoro-6-hydroxy-5-methoxydeoxypeganine, 7-iodo-6-hydroxy-5-methoxydeoxypeganine, 1,2,3,9-tetrahydro-6,7-methylenedioxypyrrolo[2,1-b]chinazoline and 2,3-dihydro-6,7-dimethoxypyrrolo[2,1-b]quinazoline-9(1H)-on.

23. (new) A method for treating schizophrenic psychosis comprising the steps of:

preparing a medicament comprising an active substance selected from the group consisting of deoxypeganine and a derivative of deoxypeganine, wherein said deoxypeganine is in the form of a free base or an acid addition salt and said derivative of deoxypeganine is simultaneously an acetylcholinesterate inhibitor and a monoamine oxidase inhibitor, and wherein said active substance is provided in a proportion between 0.1 to 90%-wt calculated as free deoxypeganine;

administering said medicament in a manner selected from the group consisting of orally, parenterally, rectally, inhalationally, transmucosally and transdermally; and

administering said medicament in a daily dose in the range of 0.1 to 100 mg.

24. (new) The method according to claim 23, wherein said acid addition salt is selected from the group consisting of deoxypeganine hydrochloride and deoxypeganine hydrobromide.